For patients who progress during therapy
with osimertinib and a subsequent platinum doublet, there are few definitive clinical data.
The CNS overall response rate (ORR) was 70 % (21 of 30 patients)
with osimertinib and 31 % with chemotherapy.
[20] In the phase III AURA3 study, the median CNS PFS was significantly longer
with osimertinib than with chemotherapy (11.7 vs 5.6 months; hazard ratio [HR], 0.32; P =.004).
On the right, the presence within EGFR of a residue able to form additional interactions
with osimertinib (as for the L718Q mutant form) prevents its reaction with Cys797 allowing EGFR to work and cancer cells to survive.
Not exact matches
Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses
osimertinib (Tagrisso) for the treatment of patients
with non — small cell lung cancer.
[21] In the recently presented FLAURA study, in which
osimertinib was used in untreated patients
with advanced EGFR - mutant NSCLC, the HR for systemic disease control and CNS control similarly favored
osimertinib over erlotinib or gefitinib, supporting the preclinical data that showed
osimertinib's penetration across the BBB and providing support for using this agent in first - line management of EGFR - mutant patients
with brain metastases.
[33] It remains unclear how the BBB permeability of AZD3759 will compare
with that of
osimertinib.